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Purpose: To assess the performance of a proton-specific knowledge based planning
(KBPP) model in creation of robustly optimized intensity-modulated proton therapy
(IMPT) plans for treatment of patients with prostate cancer.
Materials and Methods: Forty-five patients with localized prostate cancer, who had
previously been treated with volumetric modulated arc therapy, were selected and
replanned with robustly optimized IMPT. A KBPP model was generated from the results
of 30 of the patients, and the remaining 15 patient results were used for validation. The
KBPP model quality and accuracy were evaluated with the model-provided organ-at-risk
regression plots and metrics. The KBPP quality was also assessed through comparison
of expert and KBPP-generated IMPT plans for target coverage and organ-at-risk sparing.
Results: The resulting R2 (mean 6 SD, 0.87 6 0.07) between dosimetric and geometric
features, as well as the v2 test (1.17 6 0.07) between the original and estimated data,
showed the model had good quality. All the KBPP plans were clinically acceptable.
Compared with the expert plans, the KBPP plans had marginally higher dose-volume
indices for the rectum V65Gy (0.8% 6 2.94%), but delivered a lower dose to the bladder
(1.06% 6 2.9% for bladder V65Gy). In addition, KBPP plans achieved lower hotspot
(0.67Gy 6 2.17Gy) and lower integral dose (0.09Gy 6 0.3Gy) than the expert plans
did. Moreover, the KBPP generated better plans that demonstrated slightly greater
clinical target volume V95 (0.1% 6 0.68%) and lower homogeneity index
(1.13 6 2.34).
Conclusions: The results demonstrated that robustly optimized IMPT plans created by
the KBPP model are of high quality and are comparable to expert plans. Furthermore,
the KBPP model can generate more-robust and more-homogenous plans compared with
those of expert plans. More studies need to be done for the validation of the proton
KBPP model at more-complicated treatment sites.
Keywords: knowledge-based planning; IMPT; prostate cancer

cc Copyright
*

2021 The Author(s)

Introduction

Distributed under
Creative Commons CC-BY

Prostate cancer is the second most-frequent cause of cancer death among men in the
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United States and the leading cause of cancer death among men in 46 countries [1].

http://theijpt.org

Downloaded from http://meridian.allenpress.com/theijpt/article-pdf/8/2/62/2913575/i2331-5180-8-2-62.pdf by Henry Ford Health System user on 29 December 2021

Yihang Xu, BS1; Nellie Brovold, MS2; Jonathan Cyriac, MS1; Elizabeth Bossart,
PhD1; Kyle Padgett, PhD1; Michael Butkus, PhD1; Tejan Diwanj, MD1; Adam
King, MS1, Alan Dal Pra, MD1; Matt Abramowitz, MD1; Alan Pollack, MD1; Nesrin
Dogan, PhD1

Assessment of knowledge-based IMPT plans

Materials and Methods
Patient Cohort and IMPT Planning
Forty-five patients with localized prostate cancer who were previously treated with VMAT and were enrolled on a prospective
institutional review board protocol were included in this study. Patients were scanned for treatment planning in supine position
with 1.5-mm-slice thickness and had both a full bladder and an empty rectum per local protocol [24]. For all patients, the
prostate gross tumor volume, clinical target volume (CTV), bladder, rectum, and femoral heads were delineated on the
planning computed tomography (CT) scan by a radiation oncologist. The CTV consisted of prostate and proximal seminal
vesicles.
Before the planning CT scan, patients were prepared with bladder and rectal preparation protocol to comfortably fill the
bladder and release the gas inside the rectum. If gas was still detected inside the rectum in the planning CT, it was overridden
to water-equivalent density. Streaking artifacts produced by gold fiducials were also overridden to the surrounding soft-tissue
density for proton planning. Thirty IMPT plans were generated by an experienced proton dosimetrist for model configuration.
These IMPT plans employed 2 opposed lateral fields with a multifield optimization (MFO) technique using the nonlinear
universal proton optimizer (NUPO version 15.6, Eclipse, Varian Medical Systems, Palo Alto, California). Dose calculation was
performed using the proton convolution superposition algorithm (PCS version 15.6, Eclipse, Varian). A relative biological
effectiveness (RBE) of 1.1 is used for representation of the RBE-weighted dose. The prescription dose to the CTV was 78 to
80 Gy (RBE) in 38 to 40 fractions. Plans were robustly optimized using 6 5-mm setup uncertainty (in cardinal directions),
along with 6 3% proton-range uncertainty. The dose constraints for CTV were V100 (relative volume receiving more than the
prescription dose) . 99.99% and Dmax (maximum relative dose delivered to the structure) , 115%. The dose constraints for
the rectum were V40Gy (relative volume of the structure receiving . 40 Gy) , 35%, V65Gy (relative volume of the structure
receiving . 65 Gy) , 17%, and V80Gy (relative volume of the structure receiving . 80 Gy) , 10%, whereas for the bladder,
the constraints were V40Gy , 50%, V65Gy , 25%, and V80Gy , 10%. The dosimetrist made an effort to keep OAR doses
(bladder and rectum) as low as possible. The plan evaluations were then performed for the finalized plans by simulating the
6 3% proton-range uncertainty with 6 5-mm translational error in 6 directions, resulting in 12 uncertainty scenarios. In the
robust evaluation, the worst-case scenario was required to achieve V95 . 95% ( 95% of the volume receiving . 95% of the
prescription dose) for CTV.
Xu et al (2021), Int J Particle Ther
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Intensity-modulated radiation therapy (IMRT), volumetric-modulated arc therapy (VMAT), and intensity-modulated proton
therapy (IMPT), which can deliver a highly conformal dose to the tumor and spare organs at risk (OARs), are advanced
radiation-therapy techniques commonly used for treatment of prostate cancer [2, 3]. Because of the physical property of proton
beams that can eliminate the ‘‘exit dose’’ beyond the Bragg peak, proton therapy has the potential to improve the target
coverage and provide better OAR sparing compared with photon-based radiation therapy. Several publications have shown
that IMPT can deliver superior dose distributions compared with IMRT/VMAT for the treatment of prostate cancer [4, 5]. Similar
to IMRT, IMPT uses inverse-planning optimization to achieve dosimetric objectives. However, the complexity of IMPT
planning, combined with differences in the experience and skill of the planners, may result in large variations in the quality of
treatment plans, leading to suboptimal dose distribution [6–8].
Knowledge-based planning (KBP) tools, which incorporate prior treatment planning experience, have the potential to
improve the quality and consistency of treatment plans [9–13]. Numerous studies have demonstrated that KBP models are
able to generate IMRT and VMAT plans comparable to, or even better than, expert plans for a range of treatment sites [14–19].
Recently, a proton-specific KBP (KBPP) was developed to accommodate the physical traits of protons (eg, no dose beyond
the Bragg Peak) into the dose-volume histogram (DVH) estimation model [20]. A few publications have explored the
usefulness of the KBPP. Delaney et al [21] originally illustrated the concept of applying the knowledge-based DVH estimation
model to select patients (before starting optimization) to help determine those that would benefit greatly from proton therapy,
as compared to VMAT photon therapy, for patients with head and neck cancer. Their later publication demonstrated that
clinically acceptable IMPT plans can be created using a KBPP system [20, 22]. A recently published study by Cozzi et al [23]
showed that the quality of the KBPP plans were at least equivalent to the manually generated expert plans for patients with
hepatocellular carcinoma. However, more studies are necessary to both evaluate and validate the KBPP for various treatment
sites at this early stage in its use. To our knowledge, there are no studies investigating the use of KBPP for IMPT planning of
prostate cancer. In this work, we assessed the performance of a KBPP model in the creation of robustly optimized IMPT plans
for patients with prostate cancer.

Assessment of knowledge-based IMPT plans

KBP Model Configuration

Model Validation
The remaining 15 patients who were not included in the model training served as the model-validation group. For each patient
used for model validation, both MFO-based expert and KBPP-generated plans were created. The KBPP plans used the same
beam arrangement as the corresponding expert plans. For comparison purposes, the expert plans, with single-field
optimization (SFO) technique for 10 validation cases, were also created and compared with the corresponding KBPPgenerated plans using the same technique.
The KBPP plans were assessed and compared with the expert plans using the same clinical dose volume constraints for
CTV, bladder, and rectum. In addition, we assessed the integral dose deposited in the structure, which removed the CTV
volume extending 1 cm outside from the external volume contour (External  [CTV þ 1 cm]). The homogeneity index (HI) was
also evaluated for KBP-based IMPT plans and compared with that of the expert plans. In this work, the HI was defined as
follows [26]:(1)
HI ¼

D2%  D98%
3 100
Dp

where D2% is the dose to 2% of the CTV, D98% is the dose to 98% of the CTV, and Dp is the prescription dose for the CTV. The
closer the HI value is to zero, the more homogenous the plan is. Both expert- and KBP-generated IMPT plans were
normalized, such that 99.99% of the CTV volume was covered by the 100% prescription dose. To analyze the robustness of
the IMPT plan, all uncertainty scenarios and nominal plan generated from both expert and KBP plans were included for the
comparison. The comparison of the dosimetric indices between KBPP and expert plans was performed with a 2-sided paired t
test. P , .05 was considered statistically significant.

Results
Model-Training Results
Rectum, bladder, bowel, left and right femoral heads, penile bulb, and urethra were included in the model training. The R2
(mean 6 SD, 0.87 6 0.07, range, 0.79–0.99) and v2 (1.17 6 0.07, 1.09-1.29) for each OAR indicates good quality of the
model. Two potential outliers for the rectum and 3 potential outliers for the bladder were identified according to metrics in the
final model report. Figure 1 shows the regression plots and residual plots for the rectum and bladder. The regression plots
indicate the correlation between the most-important geometric-regression parameter and the main DVH parameter, which can
be used for potential geometric-outlier identification. The residual plots evaluate how the original DVH of a structure differ from
Xu et al (2021), Int J Particle Ther
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A KBPP-optimization tool (RapidPlanPT, version 16.1, Varian) was used to create the KBP library. RapidPlanPT
consists of 2 phases for model configuration: the data-extraction phase and the model-training phase. In the dataextraction phase, the geometric and dosimetric features of selected structures are parameterized for use in model
training. During the model-training phase, the DVH-estimation algorithm is applied to create a DVH-estimation model.
Individual structure objectives and priorities may be set or generated based on the training set and their principal
components. As described in Delaney et al [20], RapidPlanPT incorporates a simplified spread-out Bragg peak into the
model and uses the geometry-based expected dose metric to estimate the distance of the different voxels in each
structure from the target surfaces. Delaney et al [20] have described RapidPlanPT modeling in greater detail as well as
the differences between the photon-based model and the proton-based model in their work, so these details will not be
included in this work.
In our study, 30 IMPT plans created using the MFO technique for patients with prostate cancer were included in the proton
RapidPlan model library. A defined objective list was implemented in the model after initial model training. The priority for each
objective was set to automatically generate optimization for prospective patients. The model quality was assessed using
model-generated plots, such as DVH plots, and regression and residual plots, based on the principal-component analysis, as
well as some additional metrics to identify potential geometric and dosimetric outliers [25]. Coefficient of determination (R2)
and average Chi-square (v2) tests were applied to measure the goodness of fit of the model for each trained OAR, where the
R2 indicated the correlation between dosimetric and geometric features, whereas v2 represented the difference between the
original and the estimated data [25].

Assessment of knowledge-based IMPT plans

the estimated DVH, and they were used as a more-realistic evaluation of potential influential points that can significantly affect
the outcome of the DVH-estimation model. Although some of the points are greater than the confidence interval in the residual
plots, we think none of these points is a significant influential point because no point deviated greatly from the fitting line
isolated by itself. In the case of the isolated points (arrowed in the plots) indicated in Figure 1, the rectum was extremely large
and a greater percentage of volume was on the proton path compared with that of other cases, which was deemed an
acceptable geometric outlier in the context of the data. Based on the resulting R2, v2, and visual verification of the plots, we
decided not to exclude any other outliers. This finding is consistent with previous studies, which also showed that the removal
of outliers from a good-quality KBP model library with a sufficient population does not have a significant effect on the quality of
the plans [15, 27]

Comparison between KBPP Plans and Expert Plans
All plans generated by the KBPP were clinically acceptable, and most plans met the dose-volume constraints, except for 1
case with very small bladder, which will be discussed later. The Table shows the comparison of dosimetric indices between
the KBPP-generated and the expert plans, based on both the MFO and SFO techniques. For MFO-based plans, KBPP plans
had marginally higher dose-volume indices for the rectum V65Gy (0.8% 6 2.94%) but had lower values for all clinical bladder
dose volume indices (1.06% 6 2.9% for bladder V65Gy). In addition, the KBPP plans achieved lower hot spots
(0.67 6 2.17 Gy) and lower integral doses (0.09 6 0.3 Gy) than the expert plans did. Moreover, the better KBPP-generated
plans demonstrated slightly greater CTV V95 (0.1% 6 0.68%) and lower HI (1.13 6 2.34). For SFO-based plans, there is no
statistically significant difference for CTV coverage and HI. Nevertheless, KBPP plans based on SFO had better rectum
sparing than the expert plan had, but they had higher bladder dose-volume indices and higher hot spots. The Dmax, in the
structure External  (CTV þ 1 cm), of KBPP plans was hotter than that of the expert plans. Because the purpose of this work
was to compare KBPP plans against the expert plans, hereafter, we focus only on the results using the MFO technique
because the model was configured with all MFO-based plans.
Figure 2 shows the scatter plots of selected dose-volume indices of the nominal (red squares) and uncertainty-scenario
(gray dots) plans represented for the rectum and bladder. The dose-volume indices for rectum and bladder from KBPP plans
shows good correlation with those achieved by the expert plans. The regression coefficients for V80Gy of rectum and bladder
are relatively smaller (0.914 and 0.767, respectively), which is due to the small value of the V80Gy.
Xu et al (2021), Int J Particle Ther
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Figure 1. Regression plots and residual plot for rectum and bladder
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Table. Comparison between KBPP and expert plans for both MFO- and SFO-based plans. All uncertainty scenarios and the nominal plan were included
for the dose mean and standard deviation calculations. The same scenarios were compared with the differences calculated. Note that MFO plans were
generated for validation with 15 patients, whereas SFO plans were generated for 10 patients.
MFO, n ¼ 15

SFO, n ¼ 10

Expert,

KBPP,

KBPP-expert,

mean 6SD

mean 6SD

mean 6SD

CTV V95, %

99.09 6 1.02

99.19 6 0.91

CTV D99, Gy

74.71 6 4.05

75.09 6 4

Dose-volume indices

P value

Expert,

KBPP,

KBPP-Expert,

mean 6SD

mean 6SD

mean 6SD

P value

0.1 6 0.68

0.039

99.09 6 0.95

99.2 6 1.02

0.11 6 0.72

0.088

0.39 6 2.12

0.012

75.32 6 4.28

75.43 6 4.61

0.11 6 2.2

0.594

7.47 6 3.2

1.13 6 2.34

,0.001

6.2 6 3.27

13.82 6 9.02

14.29 6 9.44

0.47 6 4.47

0.142

12.89 6 9.17

Rectum V65Gy, %
Rectum V80Gy, %

6.03 6 5.73
1.19 6 2.18

6.83 6 6.28
1.22 6 2.28

0.8 6 2.94
0.04 6 1.16

,0.001
0.641

5.58 6 5.66
0.86 6 1.92

4.79 6 4.55
0.88 6 1.94

Bladder V40Gy, %

15.65 6 13.89

13.81 6 12.52

1.84 6 4.29

,0.001

13.1 6 14.1

13.87 6 14.75

0.77 6 1.5

,0.001

Bladder V65Gy, %

8.26 6 9.45

7.19 6 8.1

1.06 6 2.9

,0.001

6.76 6 8.93

7.55 6 9.99

0.79 6 1.64

,0.001

1.56 6 3

CTV HI

Bladder V80Gy, %
Dmax, Gy
External  (CTV þ 1 cm),

6.22 6 3.78
11.45 6 7.2

0.02 6 2.2

0.93

1.44 6 3.74

,0.001

0.78 6 2.34
0.02 6 0.32

,0.001
0.534

0.06 6 1.59

0.618

1.2 6 2.49

1.45 6 2.98

0.26 6 0.67

,0.001

84.79 6 3.01

0.67 6 2.17

,0.001

82.65 6 3.37

84.58 6 4.38

1.93 6 1.63

,0.001

1.2 6 0.45

1.11 6 0.3

0.09 6 0.3

,0.001

1.09 6 0.3

1.09 6 0.31

0 6 0.04

0.077

78.67 6 5.15

77.99 6 4.6

0.68 6 2.9

0.001

76.61 6 4.27

79.66 6 5.48

3.05 6 2.66

,0.001

1.62 6 3.27
85.45 6 2.88

Dmean, Gy
External  (CTV þ 1 cm),
Dmax, Gy

Abbreviations: KBPP, proton-specific knowledge-based planning; MFO, multifield optimization; SFO, single-field optimization; HI, homogeneity index; VxxGy, relative volume of the
structure receiving . xx Gy; Dmax, maximum relative dose delivered to the structure.
Note: Bolded values were considered statistically significant at P , .05.

Figure 3a and 3b shows box plots of the same dose-volume indices for the rectum and bladder, which further confirms that
KBP and expert plans are comparable in rectum and bladder sparing. Figure 3c is the box plot for CTV V95, demonstrating
that KBPP plans are slightly more robust than the expert plans in CTV coverage.
Figure 4a shows the average DVH of nominal plans, whereas Figure 4b consists of the average DVH, including all 13
scenarios (1 nominal plan plus 12 uncertainty scenarios). Almost no difference was observed between the KBPP and expert
plans in the CTV DVH in Figure 4a. However, when all scenarios were included, it was obvious that the CTV curve from the
KBPP plans had a sharper shoulder, reflecting that the KBPP generated more-homogenous plans.
Figure 5 is an example of both the KBPP and the expert plans failing to meet the dose constraints for the bladder because
of its extremely small volume. The expert plan exhibited slightly better dose distribution at low dose levels (Figure 5a and 5b).
Nevertheless, the KBPP plan, overall, accomplishes better bladder sparing. Figure 5c is a difference map of the KBPP and
expert plan dose distributions. This image reveals that there is a 10 to 15 Gy dose difference between the 2 plans for the
bladder region. A similar DVH curve for the rectum can be seen in Figure 5d. Comparable CTV coverage is achieved by KBPP
and expert nominal plans, but the KBPP plan is more robust when assessing the V95 from the worst-case scenarios (CTV
V95 ¼ 98.23% versus 97.41% for KBPP and expert plans, respectively).

Discussion
To our knowledge, this was the first study to explore the performance of the KBPP for robustly optimized IMPT in the treatment
of prostate cancer. This work demonstrates that the IMPT plans generated by a KBPP model were able to achieve comparable
plan quality to that of the IMPT plans generated by experts. This is consistent with the previous results on the use of the KBPP
model for IMPT planning for head and neck cancers and hepatocellular carcinoma [20, 22, 23]. One of the benefits of
employing the KBPP system for plan generation is its high efficiency. On average, each expert plan required 45 minutes to
complete iterative optimization and dose calculation. In comparison, it took about 10 minutes for KBPP plan generation. Most
KBPP plans were generated with a single optimization, whereas a subsequent ‘‘continue optimization’’ was performed for 2
cases, which took an additional 3 minutes. With respect to dosimetric indices, although the differences between the expertand KBPP-generated plans were statistically significant for the dose volume indices for rectum V65Gy (0.8% 6 2.94%), it is
likely that these differences are not clinically relevant because the magnitude of the differences was small. Statistically
significant lower dose-volume indices for bladder were found in the KBPP plans compared with the expert plans. For an
extreme case, for example, and extremely small bladder, the KBPP plan may produce better OAR sparing. The analysis that
Xu et al (2021), Int J Particle Ther
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8.61 6 3.49

Rectum V40Gy, %
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Figure 2. Dose-volume indices achieved by KBP versus expert for rectum and bladder for MFO-based plans. Red dots represent the dose-volume
indices from nominal plans while gray dots represent the ones from other uncertainty scenarios. The blue band represents the confidence interval.
Abbreviations: KBP, knowledge-based planning; MFO, multifield optimization.

included all uncertainty scenarios indicated that the plans generated by the KBPP model were more robust and homogenous
than the plans generated by the experts. Because the KBPP models accounts for robustness parameters, that increase in
robustness was anticipated. When using this model for SFO-based plans generation, KBPP-generated plans also offered
comparable plan quality to that of the expert SFO plans. We noticed that the SFO technique can provide more-robust and
Xu et al (2021), Int J Particle Ther
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-homogenous plans in terms of CTV coverage compared with the MFO-based plans, but the MFO-based plans for localized
prostate cancer were able to achieve robust coverage of the CTV, despite extreme rotational and translational alignment errors
[28]. In SFO plans, we generally observed field-specific hot spots in the range of 55% to 60% of the total dose, and in the MFO
plans, a typical field-specific hot spot was in the range of 65% to 70%, always from a beamlet near a bone junction; however,
most of the dose distribution was evenly shared between beams. However, the MFO plans were able to provide greater
volumetric coverage of the seminal vesicles for some anatomies. Because the MFO plans were able to provide satisfactory
homogeneous coverage, we believe the extra degree of freedom in planning could be used for greater sparing in abnormal
anatomies.
This study included 30 cases for model training without any outlier removal in our study. Outliers identified by the KBP
system indicate that the plan has a statistically significant difference as compared with that for the entire population in the
model. However, earlier studies by Delaney et al [27] and Hussein el al [15] compared the quality of the plans generated by an
outlier-free model to a model without outlier removal, which demonstrated that the effect of a few outliers does not significantly
affect plan quality [15, 27]. Our previous [29] also showed that the differences between the refined KBP model generated by
eliminating the dosimetric outliers and the original KBP-generated plans were insignificant. It has been reported that, in the
KBPP model for prostate cancer treatment, the initial automated-model generation setting led to inferior target coverage to that
of the expert plans, indicating more refinement of the model was required [15, 30]. In our study, we implemented defined
objectives for structures and let the model create the priority values for each objective. The KBPP plans produced by our

Figure 4. DVHs averaged over all 10 plans for KBPP and expert plans for nominal plans (a) and plans including all uncertainty scenarios (b) for MFObased plans. Abbreviations: DVH, dose-volume histogram; KBPP, proton-specific knowledge-based planning; MFO, multifield optimization.

Xu et al (2021), Int J Particle Ther
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Figure 3. Box plots of dose-volume indices with all scenarios included for (a) rectum, (b) bladder and (c) CTV for MFO based-plans. Abbreviations:
CTV, clinical target volume, MFO, multifield optimization.
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model achieved high plan quality and even better CTV coverage compared with that of the expert plans. It was reported that in
VMAT model training, the size of the models (33 versus 66 versus 97) made no difference in the plan quality for prostate cases
[29]. In this work, a proton model that included 30 cases with all contours of bladder and rectum was reliable for the simple
prostate IMPT plans.
In this work, we employed parallel-opposed lateral fields for both expert and KBPP generated robustly optimized IMPT
plans. It has been shown that IMPT plans with 3 optimized beam angles may significantly improve rectum sparing compared
with the conventional approach [31]. Furthermore, the quality of IMPT plans is more dependent on beam arrangement than
photon plans are. It is worthwhile to explore the reliability of the KBPP model when plans with different beam arrangements are
included in the model training. Future work on the integration of an algorithm with automated beam-angle selection, which is
under investigation [32], to determine whether there can be further improvement in plan quality and efficiency.
Admittedly, the prostate is a quite-simple model to start such analyses and is good practice for the application of the KBPP
model for robustly optimized IMPT plan creation. One limitation of this study is that we only included 15 patients for model
validation, which may be insufficient to confirm the reliability of the model because such analyses are in an early stage for
KBPP exploration. That said, many publications on KBP models have included small numbers of plans for validation, and
vendor recommendations are 10 validation cases to prove the model is working sufficiently [20, 29]. Further work on moreXu et al (2021), Int J Particle Ther
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Figure 5. (a and b) Isodose distributions of KBPP and expert nominal plans using MFO technique for a prostate patient included in this study. (c) The
dose difference map between KBPP and expert plan. (d) DVH for the KBPP and expert nominal plans. Abbreviations: DVH, dose-volume histogram;
KBPP, proton-specific knowledge-based planning; MFO, multifield optimization.
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complicated cases should be performed, and it is necessary that the model be validated before it can be implemented for
clinical use.

Conclusions
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